Stephania intermedia
Stephania intermedia · Accepted scientific name
Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆
Stephania intermedia is a unique medicinal plant that has drawn significant interest from pharmacological researchers. Recent studies have highlighted its potential antipsychotic activities, making it a subject of intense scientific investigation. This plant is being explored specifically for its ability to help manage the complex symptoms associated with schizophrenia. By targeting neurological pathways, its bioactive compounds may offer new avenues for psychiatric treatment. Understanding the therapeutic properties of this species could eventually lead to more effective interventions for mental health disorders.
- Synonyms
- Not available
- Common names
- Not available
- Family
- Menispermaceae
- Distribution
- Not available
- Plant Parts
- Not available
Classification
Taxonomy
Stephania intermedia is a fascinating member of the kingdom Plantae that belongs to the diverse order Ranunculales. Within this botanical classification, the species is nested inside the family Menispermaceae. It is further defined by its specific placement within the genus Stephania. Finally, this plant is categorized under the class Equisetopsida, completing its complex biological hierarchy.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Ranunculales |
| Family | Menispermaceae |
| Genus | Stephania |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Stephania intermedia is a unique botanical species primarily found within the Asia-Temperate regions. Its natural distribution is concentrated heavily throughout China, where it thrives in specific ecological niches. Within the country, the plant is particularly prevalent in the South-Central provinces. This geographic focus makes it a significant subject for studying regional biodiversity in East Asia. Understanding its specific habitat requirements is essential for anyone interested in its conservation and growth.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Biological Activities
Stephania intermedia contains an active ingredient known as (-)stepholidine, which demonstrates significant potential in treating schizophrenia. This compound functions as an antagonist for both dopamine D(1) and D(2) like receptors. Recent animal model studies have confirmed that the substance exhibits distinct antipsychotic-like effects through various behavioral tests. Specifically, research into the paw test and prepulse inhibition paradigms suggests that it can successfully reverse certain neurological disruptions. Furthermore, its unique mechanism of action may provide an atypical character that reduces the risk of common extrapyramidal side effects.
Compounds
Stephania intermedia is a Chinese herb known to contain the active ingredient stepholidine. This specific alkaloid acts as a potent antagonist for both dopamine D(1) and D(2) like receptors. Recent research has utilized animal models to explore the compound's significant potential as a unique antipsychotic drug. Studies demonstrate that stepholidine can effectively produce antipsychotic-like effects in both prepulse inhibition paradigms and paw tests. Furthermore, the substance appears to possess an atypical character, showing a relatively low tendency to induce extrapyramidal side effects.
Conditions
Stephania intermedia contains the active ingredient (-)stepholidine, which functions as a dopamine D(1) and D(2) receptor antagonist. Research using animal models indicates that this compound exhibits significant antipsychotic-like effects. Specifically, it successfully reverses the disruption of prepulse inhibition induced by apomorphine. In the paw test, the substance increased hindlimb retraction time, demonstrating potential for treating schizophrenia-related symptoms. Furthermore, its atypical character suggests it may provide these therapeutic benefits with a lower risk of inducing extrapyramidal side effects.